Gnosis by Lesaffre acquires NattoPharma to expand its vitamin K2 offerings

Alissa Marrapodi

Alissa Marrapodi is Industry Insights Contributor, Custom Content Editor, MJH Life Sciences.

The two companies will collaborate to leverage their combined capabilities to set a roadmap for the future of vitamin K2.

Gnosis by Lesaffre (Lille, France), supplier of vitaMK7, acquired NattoPharma, supplier of MenaQ7. The two companies will collaborate to leverage their combined capabilities to set a roadmap for the future of vitamin K2. 

“Vitamin K2 impacts every part of our lives,” said Gnosis by Lesaffre general manager Marc Philouze, in a press release. “From our joints to our arteries all the way down to our cells, vitamin K2 is essential for the function of several calcium-binding proteins that empower us to thrive as human beings. We’re proud to help satiate the global demand for this key ingredient by joining efforts with NattoPharma.”

“I am proud of the entrepreneurial journey accomplished by the NattoPharma team to build the vitamin K2 market and supporting science over the past decade,” added NattoPharma CEO Kjetil Ramsoy. “Lesaffre is recognized as a worldwide key player in the fermentation industry, leveraging innovation and industrial platforms to produce fermentation products; this, paired with NattoPharma’s expertise on the various forms of vitamin K2, makes us confident that we together will accelerate research and further explore K2 benefits as the true global leader in vitamin K2 with a full range of products meeting all customer needs.”